Aceto Corporation (ACET): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACET POWR Grades
- ACET scores best on the Sentiment dimension, with a Sentiment rank ahead of 82.81% of US stocks.
- ACET's strongest trending metric is Growth; it's been moving down over the last 169 days.
- ACET's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks).
ACET Stock Summary
- ACET's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 359.93 -- higher than 93.1% of US-listed equities with positive expected earnings growth.
- With a price/sales ratio of 38.09, Adicet Bio Inc has a higher such ratio than 95.55% of stocks in our set.
- Revenue growth over the past 12 months for Adicet Bio Inc comes in at 219.42%, a number that bests 96.6% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Adicet Bio Inc are SLDB, FGEN, BBIO, ATRA, and YMAB.
- Visit ACET's SEC page to see the company's official filings. To visit the company's web site, go to www.restorbio.com.
ACET Valuation Summary
- In comparison to the median Healthcare stock, ACET's price/earnings ratio is 113.15% lower, now standing at -4.8.
- Over the past 44 months, ACET's price/sales ratio has gone NA NA.
- Over the past 44 months, ACET's EV/EBIT ratio has gone up 12.2.
Below are key valuation metrics over time for ACET.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACET | 2021-08-31 | 28.7 | 1.2 | -4.8 | -1.3 |
| ACET | 2021-08-30 | 27.5 | 1.1 | -4.6 | -1.1 |
| ACET | 2021-08-27 | 27.7 | 1.1 | -4.6 | -1.1 |
| ACET | 2021-08-26 | 26.4 | 1.1 | -4.4 | -0.9 |
| ACET | 2021-08-25 | 25.2 | 1.0 | -4.2 | -0.7 |
| ACET | 2021-08-24 | 25.0 | 1.0 | -4.1 | -0.7 |
ACET's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ACET has a Quality Grade of D, ranking ahead of 8.53% of graded US stocks.
- ACET's asset turnover comes in at 0.043 -- ranking 330th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ACET's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.043 | 1 | -1.841 |
| 2021-03-31 | 0.027 | 1 | -2.369 |
| 2020-12-31 | 0.157 | 1 | -2.317 |
| 2020-09-30 | 0.031 | 1 | -3.142 |
| 2020-06-30 | 0.000 | NA | -1.790 |
| 2020-03-31 | 0.000 | NA | -1.243 |
ACET Price Target
For more insight on analysts targets of ACET, see our ACET price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $28.29 | Average Broker Recommendation | 1.21 (Strong Buy) |
ACET Stock Price Chart Interactive Chart >
ACET Price/Volume Stats
| Current price | $11.69 | 52-week high | $18.49 |
| Prev. close | $11.53 | 52-week low | $6.25 |
| Day low | $11.17 | Volume | 228,149 |
| Day high | $11.93 | Avg. volume | 304,272 |
| 50-day MA | $13.50 | Dividend yield | N/A |
| 200-day MA | $10.62 | Market Cap | 373.55M |
Aceto Corporation (ACET) Company Bio
Aceto Corporation sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company was founded in 1947 and is based in Port Washington, New York.
Latest ACET News From Around the Web
Below are the latest news stories about Adicet Bio Inc that investors may wish to consider to help them evaluate ACET as an investment opportunity.
Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesMENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a pub |
How a biotech is turning 'road bikes' into 'mountain bikes' to roll over cancerAdicet Bio Inc.'s secret is out. With a first-mover advantage in an emerging niche of cancer cell therapy and promising interim data from an early-stage clinical study, the Menlo Park company's stock has jumped as much as 61% since last Friday's close. What's more, the company is moving into a 50,305-square-foot facility in Redwood City with the goal of pushing a new therapy into clinical trials every 12 to 18 months. |
Adicet Bio, Inc. Announces Pricing of Public Offering of Common StockMENLO PARK, Calif. and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $14.00 per share. Adicet also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stoc |
Analysts’ Top Healthcare Picks: Biohaven Pharmaceutical Holding Co (BHVN), Adicet Bio (ACET)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biohaven Pharmaceutical Holding Co (BHVN – Research Report), Adicet Bio (ACET – Research Report) and Kazia Therapeutics (KZIA – Research Report) with bullish sentiments. Biohaven Pharmaceutical Holding Co (BHVN) In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Biohaven Pharmaceutical Holding Co, with a price target of $160.00. The company's shares closed last Monday at $100.24. According to TipRanks. |
Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common StockMENLO PARK, Calif. and BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that it has commenced an underwritten public offering of its common stock. Adicet also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold at the public offering price, less underwriting |
ACET Price Returns
| 1-mo | -27.26% |
| 3-mo | 35.93% |
| 6-mo | 57.97% |
| 1-year | -5.80% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -33.16% |
| 2021 | 24.48% |
| 2020 | 34.71% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...